Overview

Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis

Status:
Not yet recruiting

Trial end date:
2022-09-09

Target enrollment:

Participant gender:

Summary

The trial will be conducted as a prospective, randomized, multinational, multicenter, double-blind, placebo and active controlled trial in 4 parallel-groups of patients suffering from seasonal allergic rhinitis.

Phase:

Phase 3

Details

Lead Sponsor:

Sandoz

Treatments:

Azelastine
Mometasone Furoate